Doxil® (pegylated liposomal doxorubicin) is a standard chemotherapy drug used in women with ovarian, fallopian tube, or primary peritoneal cancer that persists despite treatment with other chemotherapy, such as paclitaxel and carboplatin. The purpose of this study is to find the highest dose of an investigational drug called veliparib (ABT-888) that can be given safely with Doxil and carboplatin in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer that has returned after initial therapy.
Veliparib is an investigational drug that kills cancer cells by preventing the repair of DNA or genetic damage in cancer cells, possibly making them more susceptible to anticancer drugs. It can also work well in cancer cells that do not have functional BRCA, a protein which helps to fix DNA damage. About 10 percent of ovarian cancer patients have mutations in BRCA genes. Veliparib is taken orally (by mouth).
This study is sponsored by the Gynecologic Oncology Group.